



Calcium Signaling and Its Dysregulation in Cancer

Guest Editor:

Dr. Randolph C. Elble

Department of Pharmacology,
Southern Illinois University
School of Medicine, Springfield,
IL 62794, USA

Deadline for manuscript
submissions:

closed (15 July 2022)

Message from the Guest Editor

Calcium is the common currency of differentiation and homeostasis. It is stored primarily in the endoplasmic reticulum, rationed according to need, and replenished from the extracellular milieu via store-operated calcium entry (SOCE). This currency is disbursed by the inositol triphosphate (IP3) receptor in response to diverse extracellular signals. The rate of release is governed by regulators of metabolism and proliferation, differentiation, autophagy, survival, and programmed cell death, with different outcomes depending on the strength of the signal and context. This system is fundamentally tumor-suppressive, and cancer cells must find ways to subvert it in order to exploit its growth-promoting effects.

This Special Issue invites both original manuscripts describing novel findings and cutting-edge review articles illustrating the many mechanisms by which cancer cells dysregulate SOCE, IP3 and ryanodine receptors, calcium transfer to mitochondria, and signaling to downstream effectors and targets to prevent cell death and enhance metabolism, mitogenesis, and metastasis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)